Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023...
What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.74%....
What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +1.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.31%. U.S. stock...
Morning Markets March S&P 500 futures (ESH2 3) this morning are up +0.74%, and March Nasdaq 100 E-Mini futures (NQH2 3) are up +0.90%. U.S. stock index futures this morning are trading higher on increased...
Thanks to sales of its Zephyr valve, the company's revenue is growing.
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW)...
Investors are reacting negatively to the company's planned securities offering.
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 5% and 9.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?